Telix Pharmaceuticals Limited

ASX:TLX Stock Report

Market Cap: AU$6.5b

Telix Pharmaceuticals Management

Management criteria checks 3/4

Telix Pharmaceuticals' CEO is Chris Behrenbruch, appointed in Jul 2023, has a tenure of 7.5 years. total yearly compensation is A$1.02M, comprised of 49% salary and 51% bonuses, including company stock and options. directly owns 6.97% of the company’s shares, worth A$452.35M. The average tenure of the management team and the board of directors is 1.7 years and 6.8 years respectively.

Key information

Chris Behrenbruch

Chief executive officer

AU$1.0m

Total compensation

CEO salary percentage49.0%
CEO tenureless than a year
CEO ownership7.0%
Management average tenure1.7yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Behrenbruch's remuneration changed compared to Telix Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

AU$32m

Dec 31 2023AU$1mAU$499k

AU$5m

Sep 30 2023n/an/a

-AU$21m

Jun 30 2023n/an/a

-AU$48m

Mar 31 2023n/an/a

-AU$77m

Dec 31 2022AU$865kAU$422k

-AU$104m

Sep 30 2022n/an/a

-AU$111m

Jun 30 2022n/an/a

-AU$119m

Mar 31 2022n/an/a

-AU$100m

Dec 31 2021AU$620kAU$374k

-AU$81m

Sep 30 2021n/an/a

-AU$70m

Jun 30 2021n/an/a

-AU$59m

Mar 31 2021n/an/a

-AU$52m

Dec 31 2020AU$421kAU$295k

-AU$45m

Sep 30 2020n/an/a

-AU$40m

Jun 30 2020n/an/a

-AU$36m

Mar 31 2020n/an/a

-AU$32m

Dec 31 2019AU$460kAU$317k

-AU$28m

Sep 30 2019n/an/a

-AU$23m

Jun 30 2019n/an/a

-AU$19m

Mar 31 2019n/an/a

-AU$16m

Dec 31 2018AU$380kAU$280k

-AU$14m

Sep 30 2018n/an/a

-AU$12m

Jun 30 2018n/an/a

-AU$10m

Mar 31 2018n/an/a

-AU$8m

Dec 31 2017AU$303kAU$211k

-AU$6m

Compensation vs Market: Chris's total compensation ($USD689.36K) is below average for companies of similar size in the Australian market ($USD2.26M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.


CEO

Chris Behrenbruch (48 yo)

less than a year

Tenure

AU$1,018,461

Compensation

Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...


Leadership Team

NamePositionTenureCompensationOwnership
Christian Behrenbruch
Co-Founderless than a yearAU$1.02m6.97%
A$ 452.3m
Darren Smith
Group Chief Financial Officer1.9yrsAU$713.90k0.0019%
A$ 125.9k
Andreas Kluge
Chief Medical Advisor & Non-Executive Directorno dataAU$43.00k6.78%
A$ 439.7m
David Cade
Group Chief Medical Officerless than a yearno data0.11%
A$ 7.2m
Richard Valeix
Group Chief Commercial Officer3.2yrsAU$902.90k0.060%
A$ 3.9m
Darren Patti
Group Chief Operating Officerless than a yearno data0.030%
A$ 1.9m
Michael Wheatcroft
Chief Scientist3.2yrsAU$167.76kno data
Craig Ulrick
Chief Information Officer1.5yrsno datano data
Kyahn Williamson
Senior Vice President of Corporate Communications & Investor Relations3yrsno datano data
Melanie Farris
Senior VP of Global Governance1.6yrsno datano data
Lena Moran-Adams
Group General Counsel1.8yrsno datano data
Thomas Fromm
Vice President of Salesno datano datano data

1.7yrs

Average Tenure

53.5yo

Average Age

Experienced Management: TLX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Christian Behrenbruch
Co-Founder7.5yrsAU$1.02m6.97%
A$ 452.3m
Andreas Kluge
Chief Medical Advisor & Non-Executive Director7.5yrsAU$43.00k6.78%
A$ 439.7m
Harry McCann
Independent Non-Executive Chairman6.8yrsAU$188.28k0.34%
A$ 22.3m
Chaitanya Divgi
Member of the Scientific Advisory Boardno datano datano data
Rodney Hicks
Member of the Scientific Advisory Boardno datano datano data
Neil Bander
Member of the Scientific Advisory Boardno datano datano data
Mark Nelson
Independent Non-Executive Director6.8yrsAU$103.30k1.08%
A$ 70.4m
Jann Skinner
Independent Non-Executive Director6.1yrsAU$111.56k0.18%
A$ 11.5m
Jean-François Chatal
Member of the Scientific Advisory Boardno datano data0.54%
A$ 34.8m
Jason Lewis
Member of the Scientific Advisory Boardno datano datano data
Klaus Kopka
Member of the Scientific Advisory Boardno datano datano data
Samuel Samnick
Member of the Scientific Advisory Boardno datano datano data

6.8yrs

Average Tenure

64yo

Average Age

Experienced Board: TLX's board of directors are considered experienced (6.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.